Advances in Therapeutics to Alleviate Cognitive Decline and Neuropsychiatric Symptoms of Alzheimer’s Disease
International Journal of Molecular Sciences · 09.05.2024 · 25 (10) · 5169
DOI: 10.3390/ijms25105169 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 09.05.2024. Verfasst von Jialin Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 136 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MRC, Alzheimer's Research UK (ARUK) Pilot grant, Alzheimer’s Research UK (ARUK) Pilot.
Themen: Demenz
Abstract (Originalsprache)
Dementia exists as a ‘progressive clinical syndrome of deteriorating mental function significant enough to interfere with activities of daily living’, with the most prevalent type of dementia being Alzheimer’s disease (AD), accounting for about 80% of diagnosed cases. AD is associated with an increased risk of comorbidity with other clinical conditions such as hypertension, diabetes, and neuropsychiatric symptoms (NPS) including, agitation, anxiety, and depression as well as increased mortality in late life. For example, up to 70% of patients diagnosed with AD are affected by anxiety. As aging is the major risk factor for AD, this represents a huge global burden in ageing populations. Over the last 10 years, significant efforts have been made to recognize the complexity of AD and understand the aetiology and pathophysiology of the disease as well as biomarkers for early detection. Yet, earlier treatment options, including acetylcholinesterase inhibitors and glutamate receptor regulators, have been limited as they work by targeting the symptoms, with only the more recent FDA-approved drugs being designed to target amyloid-β protein with the aim of slowing down the progression of the disease. However, these drugs may only help temporarily, cannot stop or reverse the disease, and do not act by reducing NPS associated with AD. The first-line treatment options for the management of NPS are selective serotonin reuptake inhibitors/selective noradrenaline reuptake inhibitors (SSRIs/SNRIs) targeting the monoaminergic system; however, they are not rational drug choices for the management of anxiety disorders since the GABAergic system has a prominent role in their development. Considering the overall treatment failures and side effects of currently available medication, there is an unmet clinical need for rationally designed therapies for anxiety disorders associated with AD. In this review, we summarize the current status of the therapy of AD and aim to highlight novel angles for future drug therapy in our ongoing efforts to alleviate the cognitive deficits and NPS associated with this devastating disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK.
ORCID-Profile: Afia B Ali
Förderung
- MRC
- Alzheimer's Research UK (ARUK) Pilot grant
- Alzheimer’s Research UK (ARUK) Pilot
Zitieren
APA
Li, J., Haj Ebrahimi, A., & Ali, A. B. (2024). Advances in Therapeutics to Alleviate Cognitive Decline and Neuropsychiatric Symptoms of Alzheimer’s Disease. International Journal of Molecular Sciences, 25(10), 5169. https://doi.org/10.3390/ijms25105169
Vancouver
Li J, Haj Ebrahimi A, Ali AB. Advances in Therapeutics to Alleviate Cognitive Decline and Neuropsychiatric Symptoms of Alzheimer’s Disease. International Journal of Molecular Sciences. 2024;25(10):5169. doi:10.3390/ijms25105169
BibTeX
@article{Li2024,
author = {Li, Jialin and Haj Ebrahimi, Anita and Ali, Afia B},
title = {Advances in Therapeutics to Alleviate Cognitive Decline and Neuropsychiatric Symptoms of Alzheimer’s Disease},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {10},
pages = {5169},
doi = {10.3390/ijms25105169}
}
EUVIMED